Description
About one third of Canadians will develop cancer during their lifetime. The survival of cancer patients is increasing because of disease screening and advances in treatment. Predictive and prognostic factors have implications for physicians, patients, healthy people in the general population and their families. Survival depends on largely on the treatment that a patient receives and much of my research involves the comparison of different treatments at the BCCA. However, survival also depends on patient characteristics and tumor factors.
Several studies are underway. One is examining lung cancer patients in BC to determine whether sunlight exposure affects their survival. That research is being led by my graduate student Asef Javan. Other studies are examining the survival of patients in BC with gastric, esophageal, breast, cervix, colorectal and oral cancer. Another study is considering survival and other outcomes for patients who undergo bone marrow transplant as part of their cancer treatment. That research is being led by my graduate student Maryam Noparast. I am also involved in several treatment/outcome projects involving clinicians at the BCCA.
Recent Publications
Neilsen TO, Andrews HN, Cheang M et al (2004); Expression of the insulin-like growth factor 1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 64:286-91
Dabiri S, Huntsman D, Makretsov N et al (2004); The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Modern Pathology 2004:1-6
Makretsov N, Huntsman D, Nielsen T et al (2004); Hierarchical clustering analysis of tissue microarray data immunostaining data identifies prognostically significant groups or breast carcinoma. Clin Cancer Res 10:6143-51
Olivotto IA, Bajdik CD, Ravdin PM et al (2005); Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol, 23:2716-25
Turbin DA, Cheang MCU, Bajdik CD et al (2006); MDM2 expression is a negative prognostic biomarker in breast carcinoma. Modern Pathology 19:69-74
Cheang MCU, Treba DO, Speers CH et al (2006); Immunohistochemical detection of estrogen receptor in breast cancer using the new rabbit monoclonal antibody SP1 predicts survival better than mouse monoclonal antibody 1D5. J Clin Oncol 24: 5637-44
Robinson A, Turbin D, Thomson T et al (2006); Human epidermal growth factor receptor status and outcome after initiation of trastuzumab-based chemotherapy in HER2+ metastatic breast cancer patients. Clin Breast Cancer 7:254-61
Crabb SJ, Bajdik CD, Leung S et al (2008); Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers: a tissue microarray feasibility study. Breast Cancer Res 10:R6
Crabb SJ, Cheang MC, Leung S et al (2008); Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node involvement in primary breast cancer. Clin Breast Cancer 8:249-56
Kennecke H, McArthur H, Olivotto IA et al (2008); Risk of recurrence among postmenopausal women with estrogen-receptor positive early breast cancer treated with adjuvant tamoxifen. Cancer 112:1437-44
Yerushalmi R, Hayes M, Gelmon K et al (2009); A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: Pathologic response, long term follow-up and correlation with biomarkers. In Press, Clin Breast Cancer 9:
Monzon JG, Cremin C, Armstrong L et al (2009); Validation of predictive models for germline mutations in DNA repair genes in colorectal cancer. Accepted, Int J Cancer, July 15, 2009
Comments/Questions about this page?